Genetic study redefines a form of excessive sweating as a treatable neurological condition
medicalxpress - An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered a major genetic cause of hyperhidrosis (chronic and excessive sweating). The study, published in Science Advances, provides strong evidence that a genetica…
AI Summary: New research identifies a genetic basis and a tiny electrically gated ion channel in nerve cells as drivers of a form of excessive sweating, recasting it as a neurological condition rather than a benign nuisance. Findings point to potential targeted therapies that address the underlying neural mechanism rather than symptom management alone.
Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early
medicalxpress - A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive im…
AI Summary: Researchers validated a blood‑based test that flags individuals at elevated risk of developing Alzheimer’s symptoms up to a decade earlier, showing strong predictive accuracy across cohorts. The finding could enable earlier monitoring and trial enrollment, but raises questions about screening protocols, follow‑up care and the psychological burden of long‑lead risk information.
- Blood biomarkers forecast Alzheimer's risk years ahead (4)
- Genetics and clearance mechanisms shaping Alzheimer's onset (3)
- Sleep, frailty and resilience as non-blood early signals (3)
Blood biomarkers forecast Alzheimer's risk years ahead
Genetics and clearance mechanisms shaping Alzheimer's onset
Sleep, frailty and resilience as non-blood early signals
2nd scan uncovers missed prostate cancer, changes care for nearly half of patients: 4 notes
Ella Jeffries / beckershospitalreview - A second scan using prostate-specific membrane antigen positron emission tomography changed treatment plans for nearly half of patients with recurrent prostate cancer whose initial scan was negative, according to research published in the July issue of Th…
AI Summary: Follow-up prostate-specific membrane antigen (PSMA) PET imaging uncovered disease missed on initial scans and altered management in nearly half of patients. Repeat imaging revealed occult or more extensive disease, prompting switches from surveillance to definitive or systemic therapies and adjustments to radiation plans. The data argue for selective reimaging when staging is uncertain.
Former Mayo Clinic Leader Sues System Over Alleged AI Cover-Up: 6 Things to Know
Katie Adams / medcitynews - A former Mayo Clinic research director claims she was silenced, demoted and ultimately fired for sounding the alarm on AI safety and patient privacy lapses at the health system. Traci Tamiko Eto is now suing Mayo for retaliation.The post Former Mayo Clini…
AI Summary: A former Mayo Clinic research director has filed suit alleging retaliation after raising concerns about the health system’s use and oversight of clinical AI. The complaint accuses leadership of suppressing warnings, sidelining the whistleblower and covering up problematic practices — seeking damages and reforms while triggering closer scrutiny of institutional AI governance.
- Clinical AI expansion, partnerships and industry pitfalls (5)
- Mayo whistleblower lawsuit alleges AI cover-up (3)
Clinical AI expansion, partnerships and industry pitfalls
Mayo whistleblower lawsuit alleges AI cover-up
Breast Cancer Incidence Is Rising Rapidly Among Asian American, Native Hawaiian, and Pacific Islander Women
oncodaily - Breast cancer incidence is increasing rapidly among Asian American, Native Hawaiian, and Pacific Islander women in the United States, with especially concerning trends in early-onset disease, distant-stage diagnosis, and aggressive […]
AI Summary: New research shows a rapid rise in breast cancer incidence among Asian American, Native Hawaiian and Pacific Islander women, highlighting shifting epidemiology and unmet screening needs. The findings call for tailored public health strategies, culturally competent outreach and earlier detection efforts to address an alarming trend in populations historically considered lower risk.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
Two tests GPs can soon offer to help spot endometriosis
bbc - Experts hope they will be a game-changer and cut the nine-year or longer diagnosis waits patients can currently face.
AI Summary: Emerging research on hormonal signatures and blood biomarkers has led to development of tests GPs may soon use to spot endometriosis earlier. Patient accounts underline the life‑changing potential of timely diagnosis. The work promises less guesswork, fewer invasive procedures, and fewer years lost to unexplained pain—so yes, medicine might actually make life convenient for once.
- GP tests and NHS rollout to shorten diagnosis (3)
- Hormone and symptom research reveals diagnostic signatures (3)
- Work, wellbeing and cost pressures on patients (3)
GP tests and NHS rollout to shorten diagnosis
Hormone and symptom research reveals diagnostic signatures
Work, wellbeing and cost pressures on patients
A Legionnaires' Disease Outbreak Has Sickened 28 People in New York City — Here's What to Know
discovermagazine - Learn more about Legionnaires' disease and what the source of the current outbreak in New York City may be.
AI Summary: An outbreak of Legionnaires’ disease has sickened multiple residents and visitors on Manhattan’s Upper East Side, triggering public-health investigations, building inspections and water-system testing. Officials are working to identify the source and contain the spread while urging clinicians to consider Legionnaires’ in patients with pneumonia-like symptoms.
- Early cluster: initial cases and local spread (3)
- Widening outbreak: building positives and first death (5)
Early cluster: initial cases and local spread
Widening outbreak: building positives and first death
American Cancer Society Reports Latest Global Cancer Statistics; Cancer Cases Approach 21 Million Worldwide, With Burden Projected to Surge 67% by 2050
cancer - New data reveal stark geographic inequities and call for urgent global action on prevention, early detection, and equitable treatment access
AI Summary: The American Cancer Society published updated global cancer statistics showing cases near 21 million and projecting a steep rise by midcentury, highlighting shifting incidence patterns and growing health system strain. The report calls for intensified prevention, screening and investment in equitable cancer control to blunt the projected surge.
- Cancer-type disparities: breast, GI, GU survival gaps (5)
- Global cancer estimates and headline numbers (6)
- WHO report launch and global call to action (5)
- All Other Stories
Cancer-type disparities: breast, GI, GU survival gaps
Global cancer estimates and headline numbers
WHO report launch and global call to action
All Other Stories
Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- COMPASS: pan-cancer AI predicting immunotherapy response (6)
- Tumor-specific predictors and clinical nuance in immunotherapy (3)
COMPASS: pan-cancer AI predicting immunotherapy response
Tumor-specific predictors and clinical nuance in immunotherapy
AI system detects sudden cardiac death risk, identifying thousands more patients annually
medicalxpress - Each year in the U.S., more than 300,000 people die from sudden cardiac arrest, a condition in which the heart's electrical system malfunctions without warning. The medical emergency can kill both high-risk older adults and young athletes with no history …
AI Summary: New AI tools claim to identify far more patients at risk of sudden cardiac death than traditional metrics, detecting subtle patterns invisible to clinicians. Early studies suggest strong sensitivity gains, but experts caution that screening scale‑up, false positives and prospective validation will determine whether the tech saves lives or simply creates more testing.
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.
Jeremy Clarkson’s Prostate Cancer Story: Early Detection, Treatment, and Remission
oncodaily - Jeremy Clarkson has revealed that he was diagnosed with an aggressive form of prostate cancer that was caught early. The broadcaster shared the diagnosis in the final episodes of Clarkson’s […]
AI Summary: Jeremy Clarkson publicly revealed an aggressive prostate cancer diagnosis, underwent early detection and treatment, and is now in remission. The case highlights the value of prompt screening and modern therapies — and proves even TV personalities can be very boringly human when faced with routine medicine.
Ebola outbreak is 3x larger at 4 weeks than any before: 6 updates
Mariah Taylor / beckershospitalreview - The current Bundibugyo Ebola outbreak is three times larger than any previous Ebola outbreak four weeks after being declared a public health emergency, Africa CDC epidemiologist Wessam Mankoula, MD, said in a briefing. The largest Ebola outbreak in histor…
AI Summary: The Ebola outbreak has escalated rapidly, outpacing previous episodes with case counts multiplying within weeks and official tallies surpassing 1,000 in affected regions. Clinicians note that current presentations can begin like a mild flu, raising detection challenges even as mortality remains significant. Public-health teams warn vigilance and rapid response remain critical.
- Milder symptoms complicate detection; treatment trials begin (5)
- Outbreak surges and regional spread (6)
- U.S. and global emergency response ramps up (4)
- All Other Stories
Milder symptoms complicate detection; treatment trials begin
Outbreak surges and regional spread
U.S. and global emergency response ramps up
All Other Stories
Early-onset cancers are on the rise: Knowing family history is crucial
medicalxpress - In the U.S., more than a dozen kinds of cancer are on the rise in adults under 50. Among these early-onset cancers, colorectal and breast cancers have increased the most, and colorectal cancer is now the deadliest cancer for Americans ages 18 to 49.
AI Summary: New analyses show early‑onset cancers are increasing and reinforce that detailed family history remains a key tool for risk assessment and targeted screening. Experts urged clinicians and health systems to prioritize family‑history collection and cascade testing to catch at‑risk individuals sooner and reduce preventable morbidity.
- Breast cancer risk: AI tools, polygenic scores, prevention (5)
- Colorectal cancer: rising cases and screening gaps worldwide (6)
- Faster biological aging linked to early-onset cancer rise (5)
- Inherited cancer risk and genomics driving early diagnoses (6)
- All Other Stories
Breast cancer risk: AI tools, polygenic scores, prevention
Colorectal cancer: rising cases and screening gaps worldwide
Faster biological aging linked to early-onset cancer rise
Inherited cancer risk and genomics driving early diagnoses
All Other Stories
Novel electronic health record-based marker can identify at-risk transplant patients and reduce organ rejection
medicalxpress - A new multicenter study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that a novel electronic health record-based marker can help clinicians identify transplant patients at high risk for organ rejection because they are not ta…
AI Summary: Teams developed and validated an electronic‑health‑record derived marker that flags transplant recipients at elevated risk of organ rejection. The tool integrates routinely collected clinical data to trigger earlier review and intervention, promising to reduce rejection events if deployed thoughtfully within clinical workflows rather than buried in another alert pile.
IRhythm discloses data stolen from third-party applications in cyberattack
Ricky Zipp / healthcaredive - The cardiac monitoring company said that a threat actor has demanded payment in exchange for not publicly releasing the stolen data.
AI Summary: IRhythm announced a cybersecurity incident involving stolen data from third‑party applications and is investigating the breach. Limited patient information may have been exposed, prompting notifications and security reviews. The episode starkly illustrates how digital‑health vendors remain attractive targets and how compromises of ancillary systems can ripple into real patient risk.
Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
Ultrasensitive blood test predicts head and neck cancer relapse months earlier
medicalxpress - A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after …
AI Summary: Researchers validated an ultrasensitive HPV whole‑genome sequencing blood assay that detects minimal residual disease after surgery for HPV‑positive head and neck cancer, flagging relapse months before clinical signs. Early detection could enable earlier salvage therapy and closer surveillance, potentially changing follow‑up care and improving outcomes for this patient group.